VIVIANA A SIMON

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H
    Mawuena Binka
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA
    J Virol 86:49-59. 2012
  2. ncbi Immune mechanisms of HIV control
    Lisa A Chakrabarti
    Institut Pasteur, Unité d Immunogénétique Cellulaire, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    Curr Opin Immunol 22:488-96. 2010
  3. ncbi HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    Lancet 368:489-504. 2006
  4. ncbi HIV-1 dynamics in vivo: implications for therapy
    Viviana Simon
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nat Rev Microbiol 1:181-90. 2003
  5. ncbi Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
  6. ncbi Characterization of HIV-1 integrase N-terminal mutant viruses
    Aliza G Lloyd
    The Aaron Diamond AIDS Research Center 455 First Avenue, New York, NY 10016, USA
    Virology 360:129-35. 2007
  7. ncbi Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques
    Nataliya Trunova
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 352:169-77. 2006
  8. ncbi Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience
    Anita Shet
    Aaron Diamond AIDS Research Center (an affiliate of the Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 41:439-46. 2006
  9. ncbi Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
  10. ncbi Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003

Research Grants

  1. Mechanisms of multi-drug resistant HIV-1 adaptation
    Viviana Simon; Fiscal Year: 2003
  2. HIV-1 evolution driven by intracellular defenses
    Viviana Simon; Fiscal Year: 2006
  3. HIV-1 evolution driven by intracellular defenses
    Viviana Simon; Fiscal Year: 2009
  4. Genomic Determinants of Intrinsic Antiviral Host Defenses
    VIVIANA A SIMON; Fiscal Year: 2010

Collaborators

Detail Information

Publications16

  1. ncbi The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H
    Mawuena Binka
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA
    J Virol 86:49-59. 2012
    ....
  2. ncbi Immune mechanisms of HIV control
    Lisa A Chakrabarti
    Institut Pasteur, Unité d Immunogénétique Cellulaire, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    Curr Opin Immunol 22:488-96. 2010
    ..This review will focus on recent advances in understanding the immune mechanisms of HIV control, and on the lessons that may be drawn for the development of candidate HIV vaccines...
  3. ncbi HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    Lancet 368:489-504. 2006
    ..This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1...
  4. ncbi HIV-1 dynamics in vivo: implications for therapy
    Viviana Simon
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nat Rev Microbiol 1:181-90. 2003
    ..We also discuss the obstacles that result from the ability of HIV-1 to remain dormant for a prolonged period of time in a subset of long-lived cells, despite an apparently effective antiretroviral treatment...
  5. ncbi Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
    ....
  6. ncbi Characterization of HIV-1 integrase N-terminal mutant viruses
    Aliza G Lloyd
    The Aaron Diamond AIDS Research Center 455 First Avenue, New York, NY 10016, USA
    Virology 360:129-35. 2007
    ..We propose that the severe deficiency of these mutants exert a strong selective pressure that leads to the near total conservation of the N-terminal residue of integrase in HIV-1, HIV-2 and SIV...
  7. ncbi Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques
    Nataliya Trunova
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 352:169-77. 2006
    ....
  8. ncbi Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience
    Anita Shet
    Aaron Diamond AIDS Research Center (an affiliate of the Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 41:439-46. 2006
    ....
  9. ncbi Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
    ..Additional studies are needed to understand the host- and pathogen-related determinants of incomplete pharmacologic control of HIV-1 replication...
  10. ncbi Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003
    ..Further studies are needed to elucidate the precise regions that are essential for these characteristics...
  11. ncbi Determining the relative efficacy of highly active antiretroviral therapy
    Michael Louie
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
    J Infect Dis 187:896-900. 2003
    ..Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted...
  12. ncbi Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
    Michael Louie
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    AIDS 17:1151-6. 2003
    ..These data support further study of TDF-based regimens in simplified combinations of antiviral agents as initial treatment for chronic HIV-1 infection...
  13. ncbi Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes
    Lubbertus C F Mulder
    Mount Sinai School of Medicine, Department of Medicine, The Global Health and Emerging Pathogens Institute, New York, New York 10029, USA
    J Virol 84:9613-7. 2010
    ..Lastly, the endogenous A3F mRNA and protein expression levels in PBMCs were considerably lower than those of A3G. Our results suggest that A3F neutralization is dispensable for HIV-1 replication in primary human T-lymphocytes...
  14. ncbi Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York 1016, USA
    AIDS 16:1511-9. 2002
    ..The latter findings suggest transmission of viruses from subjects who have either changed or discontinued therapy...
  15. ncbi Cytidine deamination induced HIV-1 drug resistance
    Lubbertus C F Mulder
    Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1090, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:5501-6. 2008
    ....
  16. ncbi The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity
    Marcel Ooms
    Division of Infectious Diseases, Department of Medicine, and Department of Microbiology, Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Virol 84:7961-9. 2010
    ..Thus, the antiviral activity of A3H haplotypes is determined by its incorporation into the viral core, in proximity to the reverse transcription complex...

Research Grants9

  1. Mechanisms of multi-drug resistant HIV-1 adaptation
    Viviana Simon; Fiscal Year: 2003
    ..In this way we will gain insight into the special challenges posed by compensatory adaptations displayed by some HIV-1 strains in the face of drug treatment. ..
  2. HIV-1 evolution driven by intracellular defenses
    Viviana Simon; Fiscal Year: 2006
    ..abstract_text> ..
  3. HIV-1 evolution driven by intracellular defenses
    Viviana Simon; Fiscal Year: 2009
    ..abstract_text> ..
  4. Genomic Determinants of Intrinsic Antiviral Host Defenses
    VIVIANA A SIMON; Fiscal Year: 2010
    ..The goal of this proposal is to determine the degree of structural genomic variation within the APOBEC 3 locus, and to assess how variability of these intrinsic resistance genes impacts on HIV-1 replication. ..